The prion protein in human neuromuscular diseases.
The basis of human prion diseases affecting the nervous system is accumulation of a disease-associated conformer (PrPSc) of the normal cellular prion protein (PrPC). Earlier studies demonstrated increased expression of PrPC in inclusion body myositis (IBM), dermato-, and polymyositis, as well as neurogenic muscle atrophy. To define the spectrum and reliability of PrPC immunoreactivity, its expression was examined systematically in a series of pathologically characterized muscular disorders by means of immunohistochemistry, confocal laser microscopy, and immunogold electron microscopy. Anti-PrPC immunolabelling of rimmed vacuoles was observed in IBM, inclusions of myofibrillary myopathy, targets, regenerating, and atrophic fibres, mononuclear cells, in addition to ragged red fibres in mitochondrial myopathies, and focal sarcolemmal immunostaining in non-diseased controls. Quantitative analysis demonstrated that, in neurogenic muscle lesions, anti-PrPC staining detects a significantly broader spectrum of fibres than anti-vimentin or anti-NCAM. In dystrophic muscle, PrPC expression was mainly restricted to regenerating fibres. In IBM, PrPC expression was not confined to rimmed vacuoles or vacuolated fibres and only a small percentage (7.1%) of rimmed vacuoles were PrPC positive. Ultrastructurally, PrPC was observed in the cytoplasm of lymphocytes, in the myofibrillar network of targets, and in rimmed vacuoles. Knowledge of disease circumstances with altered expression of PrPC is important in the setting of a potentially increased chance for extraneural PrPC-PrPSc conversion. In addition, our observations suggest that PrPC may have a general stress-response effect in various neuromuscular disorders.
National Institute of Psychiatry and Neurology, Budapest, Hungary.
Gábor G
GG
Kovács
Ognian
O
Kalev
Ellen
E
Gelpi
Christine
C
Haberler
Julia
J
Wanschitz
Michaela
M
Strohschneider
Mária J
MJ
Molnár
Lajos
L
László
Herbert
H
Budka
D002908:Chronic Disease; D003882:Dermatomyositis / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D018613:Microscopy, Confocal / Q000379:methods; D008854:Microscopy, Electron / Q000379:methods; D018485:Muscle Fibers, Skeletal / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009136:Muscular Dystrophies / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018979:Myositis, Inclusion Body / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D009468:Neuromuscular Diseases / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D017285:Polymyositis / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D011328:Prions / Q000032:analysis*; D014617:Vacuoles / Q000473:pathology; D014746:Vimentin / Q000032:analysis
D011328:Prions; D014746:Vimentin